Name: Hashimoto’s Thyroiditis Drug Market Insights | USA | Japan | Europe
Creator: DataM Intelligence
Published: Mon Sep 25 2023 15:47:02 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions
Keywords: hashimoto’s thyroiditis drug market

Hashimoto’s Thyroiditis Drug Market Insights | USA | Japan | Europe

Hashimoto's Thyroiditis Drug Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Hashimoto&#39;s Thyroiditis Drug Market is Segmented&nbsp;By Drug(Introduction, LevothyroxineTriiodothyronine, Desiccated Thyroid Extract, Others),&nbsp;By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Other),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

<blockquote>
Hashimoto&#39;s thyroiditis drug market is estimated to grow&nbsp;at a high CAGR 5.5% during the forecast period (2023-2030).
</blockquote>

The most common cause of hypothyroidism in the United States is Hashimoto&#39;s thyroiditis, also known as chronic lymphocytic thyroiditis. It is an autoimmune condition that causes chronic thyroid inflammation. This illness is more likely to run in families.

<h3>Hashimoto&#39;s Thyroiditis Drug Market Dynamics</h3>

The factors influencing the global hashimoto&#39;s thyroiditis drug market are the increasing research and development and the growing prevalence of hashimoto&#39;s thyroiditis.

The increasing research and development are expected to drive the hashimoto&#39;s thyroiditis drug market

Hashimoto thyroiditis is also known as chronic autoimmune thyroiditis or chronic lymphocytic thyroiditis. It is an autoimmune disease in which thyroid cells are destroyed by immune processes involving cells and antibodies. In developed countries, it is the most common cause of hypothyroidism. On the other hand, inadequate dietary iodine intake is the most common cause of hypothyroidism worldwide. The formation of antithyroid antibodies that attack the thyroid tissue, causing progressive fibrosis, is the pathophysiology of Hashimoto&#39;s thyroiditis. Because diagnosis is difficult, the condition is sometimes not discovered until late in the disease process. Increased thyroid-stimulating hormone (TSH) and low thyroxine (T4) levels, as well as increased antithyroid peroxidase (anti-TPO) antibodies, are the most common laboratory findings. This activity examines the pathophysiology, diagnosis, and treatment of Hashimoto thyroiditis, focusing on the role of the interprofessional team inpatient care. Women are more likely to be affected than men. At least a 10:1 female-to-male ratio exists. Although some sources suggest that most women are diagnosed between the ages of 30 and 50. The standard treatment is levothyroxine, given at a dose of 1.6 to 1.8 mcg/kg/day. T4 is converted to T3, the active form of thyroid hormone, in the human body. Moreover, thyroid hormone replacement is the cornerstone of hypothyroidism treatment. Orally administered titrated levothyroxine sodium is the drug of choice. It has a 7-day half-life and can be taken daily. Avoiding suboptimal absorption should not be taken with iron or calcium supplements, aluminium hydroxide, or proton pump inhibitors. Take it on an empty stomach first thing in the morning for best absorption.

The side effects associated with the drugs are expected to hamper the market growth

Generally, because levothyroxine mimics natural T-4 in the body, there are usually no negative side effects if the treatment produces &quot;natural&quot; T-4 levels in the body. Too much thyroid hormone can exacerbate bone loss, resulting in brittle, weak bones (osteoporosis) or cause irregular heartbeats (arrhythmias). T-4 is converted to triiodothyronine, a thyroid hormone that is naturally produced (T-3). The T-4 replacement hormone is also converted to T-3, and for most people, T-4 replacement therapy provides an adequate supply of T-3. A synthetic T-3 hormone (Cytomel) or a synthetic T-4 and T-3 combination may be prescribed by a doctor for people who need better symptom control. Rapid heartbeat, insomnia, and anxiety are all side effects of T-3 hormone replacement therapy. A 3- to 6-month trial period may be used to evaluate these treatments.

<h3>COVID-19 Impact Analysis</h3>

Thyroid dysfunction was found in approximately 15% of patients with mild to moderate COVID-19. SARS-CoV-2 is thought to directly impact thyroid morphology and function, potentially worsening pre-existing AITD. Furthermore, COVID-19&#39;s effects on the immune system may aggravate AITD and lead to the development of cytokine storms. Nonetheless, it is unclear whether patients with autoimmune diseases have a higher risk of a poor outcome, even if those who receive immune-modulatory therapy don&#39;t appear to have a higher risk. Thyroid dysfunction may increase susceptibility to COVID-19 infection, which warrants further investigation. While COVID-19 is linked to non-thyroidal illness, it is unclear whether it also raises the risk of developing thyroid cancer. Hence, the impact of covid-19 is expected to accelerate the demand for hashimoto&#39;s thyroiditis drug market.

<h3>Hashimoto&#39;s Thyroiditis Drug Market Segment Analysis</h3>

Levothyroxine segment is expected to dominate the market growth 

To treat hypothyroidism, most people with Hashimoto&#39;s disease take medication. The synthetic hormone levothyroxine is used to treat hypothyroidism caused by Hashimoto&#39;s disease (Levoxyl, Synthroid, others). The synthetic hormone functions similarly to the T-4 hormone produced naturally by the thyroid. Hypothyroidism is usually treated with synthetic thyroxine (T4), also known as levothyroxine, and sold under Synthroid, Tirosint, Levothroid, Levo-T, Levoxyl, and Unithroid. This medication is usually taken once a day consistently. It replaces thyroid hormones and alleviates hypothyroidism symptoms. Finding the right dose may take some trial and error, and the medication must be taken for the rest of one&#39;s life. Because of the possible link between subclinical hypothyroidism and heart disease, treatment with levothyroxine may be appropriate for people under 65 with a TSH level in this range. Levothyroxine is usually only prescribed to patients 65 and older who also have hypothyroid symptoms. To achieve euthyroid status, 0.10 to 0.15 mg of levothyroxine per day is required. Children may require up to 4 g per kg per day for complete replacement. Thyroid hormone replacement can begin near the target goal in young patients with no risk factors for cardiovascular disease.

<h3>Hashimoto&#39;s Thyroiditis Drug Market</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			5.5%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Drug,&nbsp;By Distribution Channel, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Hashimoto&#39;s Thyroiditis Drug Market Geographical Analysis</h3>

North America region is expected to hold the largest market share in the global hashimoto&#39;s thyroiditis drug market

The growing prevalence of hashimoto&#39;s thyroiditis and increasing research and development in this region is expected to drive the market growth.

In the United States, 1 to 2% of the population has Hashimoto thyroiditis. It affects women more frequently than men due to hormonal factors. In the United States, this is the most common cause of thyroid underactivity (hypothyroidism). Moreover, the increasing US FDA approvals is expected to drive the market growth. For instance, on 21st January 2019, Lupin received approval from the US Food and Drug Administration to market Levothyroxine Sodium tablets used to treat hypothyroidism. The USFDA has given the company permission to market the tablets in the following strengths: 25 micrograms (mcg), 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg.

<h3>Hashimoto&#39;s Thyroiditis Drug Market Competitive Landscape</h3>

The global hashimoto&#39;s thyroiditis drug market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Acella Pharmaceuticals, LLC, AbbVie Inc, Pfizer Inc, Lannett, Amneal Pharmaceuticals LLC, Lupin, Jerome Stevens Pharmaceuticals, Inc., Bioiberica S.A.U., IBSA Pharma Inc.

Lupin Pharmaceuticals, Inc.

Overview: Lupin Limited is a multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the most profitable generic pharmaceutical firms in the world. Pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis are among the company&#39;s key focus areas. The company was founded in 1968.

Product Portfolio: Levothyroxine sodium tablet is levothyroxine sodium (T4) indicated for Hypothyroidism as replacement therapy in congenital or acquired Hypothyroidism, primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic). Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: Used in treating thyrotropin-dependent well-differentiated thyroid cancer as an adjunct to surgery and radioiodine therapy.

<ol>
	<li>Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet By Drug</li>
		<li>Market Snippet By Distribution Channel</li>
		<li>Market Snippet By Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>The increasing research and development</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects associated with the drugs</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis 
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Drug
	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
		<li>Market Attractiveness Index, By Drug
		<ol>
			<li>Levothyroxine*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
			</ol>
			</li>
			<li>Triiodothyronine</li>
			<li>Desiccated Thyroid Extract</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>&nbsp;Other</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>&nbsp;Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Lupin Pharmaceuticals, Inc.*
		<ol>
			<li>&nbsp;Company Overview</li>
			<li>&nbsp;Product Portfolio and Description</li>
			<li>&nbsp;Key Highlights</li>
			<li>&nbsp;Financial Overview</li>
		</ol>
		</li>
		<li>AbbVie Inc</li>
		<li>Pfizer Inc</li>
		<li>Bioiberica S.A.U.</li>
		<li>Acella Pharmaceuticals, LLC</li>
		<li>Lannett</li>
		<li>IBSA Pharma Inc.</li>
		<li>Amneal Pharmaceuticals LLC</li>
		<li>Jerome Stevens Pharmaceuticals, Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>&nbsp;Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 01 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022, 2026 &amp; 2030 ($ Million)

Table 02 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table 03 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table 04 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022, 2026 &amp; 2030 ($ Million)

Table 05 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 06 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table 07 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 08 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table 09 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Region, 2022-2030 ($ Million)

Table 10 North America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 11 North America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 12 North America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Country, 2022-2030 ($ Million)

Table 13 South America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 14 South America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 15 South America Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Country, 2022-2030 ($ Million)

Table 16 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 17 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 18 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Country, 2022-2030 ($ Million)

Table 19 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 20 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 21 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Country, 2022-2030 ($ Million)

Table 22 Middle East &amp; Africa Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Drug, 2022-2030 ($ Million)

Table 23 Middle East &amp; Africa Hashimoto&rsquo;s Thyroiditis Drug Market Value, By Distribution Channel, 2022-2030 ($ Million)

Table 24 Lupin Pharmaceuticals, Inc.: Overview

Table 25 Lupin Pharmaceuticals, Inc.: Product Portfolio

Table 26 Lupin Pharmaceuticals, Inc.: Key Developments

Table 27 AbbVie Inc: Overview

Table 28 AbbVie Inc: Product Portfolio

Table 29 AbbVie Inc: Key Developments

Table 30 Pfizer Inc: Overview

Table 31 Pfizer Inc: Product Portfolio

Table 32 Pfizer Inc: Key Developments

Table 33 Bioiberica S.A.U.: Overview

Table 34 Bioiberica S.A.U.: Product Portfolio

Table 35 Bioiberica S.A.U.: Key Developments

Table 36 Acella Pharmaceuticals, LLC: Overview

Table 37 Acella Pharmaceuticals, LLC: Product Portfolio

Table 38 Acella Pharmaceuticals, LLC: Key Developments

Table 39 Lannett: Overview

Table 40 Lannett: Product Portfolio

Table 41 Lannett: Key Developments

Table 42 IBSA Pharma Inc.: Overview

Table 43 IBSA Pharma Inc.: Product Portfolio

Table 44 IBSA Pharma Inc.: Key Developments

Table 45 Amneal Pharmaceuticals LLC: Overview

Table 46 Amneal Pharmaceuticals LLC: Product Portfolio

Table 47 Amneal Pharmaceuticals LLC: Key Developments

Table 48 Jerome Stevens Pharmaceuticals, Inc: Overview

Table 49 Jerome Stevens Pharmaceuticals, Inc: Product Portfolio

Table 50 Jerome Stevens Pharmaceuticals, Inc: Key Developments

List of Figures

Figure 01 Global Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 02 Global Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 03 Global Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Region, 2022 &amp; 2030 (%)

Figure 04 Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 05 Global Hashimoto&rsquo;s Thyroiditis Drug Market Y-o-Y Growth By Drug, 2022-2030 (%)

Figure 06 Levothyroxine: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 07 Triiodothyronine: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 08 Desiccated Thyroid Extract: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 09 Others: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 10 Global Hashimoto&rsquo;s Thyroiditis Drug Market Y-o-Y Growth By Distribution Channel, 2022-2030 (%)

Figure 11 Hospital Pharmacies: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 12 Retail Pharmacies: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 13 Other: Global Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 14 Global Hashimoto&rsquo;s Thyroiditis Drug Market Y-o-Y Growth By Region, 2022-2030 (%)

Figure 15 North America Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 16 North America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 17 North America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 18 North America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 19 South America Hashimoto&rsquo;s Thyroiditis Drug Market Share, 2022-2030 ($ Million)

Figure 20 South America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 21 South America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 22 South America Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 23 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 24 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 25 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 26 Europe Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 27 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 28 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 29 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 30 Asia-Pacific Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 31 Middle East &amp; Africa Hashimoto&rsquo;s Thyroiditis Drug Market Value, 2022-2030 ($ Million)

Figure 32 Middle East &amp; Africa Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Drug, 2022 &amp; 2030 (%)

Figure 33 Middle East &amp; Africa Hashimoto&rsquo;s Thyroiditis Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 34 Lupin Pharmaceuticals, Inc.: Financials

Figure 35 AbbVie Inc: Financials

Figure 36 Pfizer Inc: Financials

Figure 37 Bioiberica S.A.U.: Financials

Figure 38 Acella Pharmaceuticals, LLC: Financials

Figure 39 Lannett: Financials

Figure 40 IBSA Pharma Inc.: Financials

Figure 41 Amneal Pharmaceuticals LLC: Financials

Figure 42 Jerome Stevens Pharmaceuticals, Inc: Financials

Hashimoto's Thyroiditis Drug Market Size, Share, Industry, Forecast and outlook (2023-2030)

Pyrethroid Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 26

Starting from

Thyroid Ablation Devices Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2024 November 18

Starting from

Thyroid Function Tests Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 May 17

Starting from

Thyroid Gland Disorders Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 16

Starting from

Parathyroid Hormone Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2024 February 07

Starting from

Hyperparathyroidism Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 November 14

Starting from